Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desipramine in SCLC and High-Grade Neuroendocrine Tumors
NCT01719861Phase 2Terminated
- Sponsor
- Joel Neal
- Start
- Oct 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of desipramine in small cell lung cancer (SCLC), Neuroendocrine Neoplasm (NEN), sponsored by Joel Neal. Started Oct 2012; status: terminated.
02
Drugs
desipramine
03
Conditions
small cell lung cancer (SCLC)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT01719861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01719861.